AXXAM SPA, a number one provider of integrated early drug discovery services, and B’Sys GmbH, specialist for ion channel biology, are pleased to announce strategic cooperation with the enabled access to validated ion channel cell lines for HIT and lead identification through extensive cross-wide electrophysiological templates.
B’Sys offers an intensive catalog of technical cell lines that express a wide selection of ion channels. Through this cooperation, Axxam will use his deep specialist knowledge in biology and high-through-replacement screening to validate chosen B’sys Cell lines on automated patch clamp platforms, including Axxam’s SP384 systems.
This joint initiative offers a singular advantage of pharmaceutical and biotech customers: the power to acquire validated, high-quality ion channel cell lines which can be suitable for the demanding applications for drug discoveries. These validated lines are subjected to strict performance-based tests to make sure that they meet the strict criteria required for downstream campaigns for high-throughput screening (HTS).
said Daniel Konrad, CEO of B’Sys.
